Desmyter J, Bradburne A F, Vermylen C, Daneels R, Boelaert J
Lancet. 1975 Aug 30;2(7931):376-7.
In a double-blind study, hepatitis-B immunoglobulin significantly protected patients in a haemodialysis unit against the development of HBs antigenaemia, compared to control patients receiving normal human immunoglobulin (p less than 0-01). Injections were given at the beginning and after 6 months, and observations extended over 16 months. Analysis of antiHBc and anti-HBs antibodies suggested that neutralisation of the virus inoculum, as well as modification of infection, may be implicated in the prevention of HBs antigenaemia.
在一项双盲研究中，与接受正常人免疫球蛋白的对照患者相比，乙肝免疫球蛋白显著保护了血液透析单位的患者免于发生乙肝表面抗原血症（P<0.01）。在开始时和6个月后进行注射，观察期长达16个月。对抗乙肝核心抗体和乙肝表面抗体的分析表明，病毒接种物的中和以及感染的改变可能与预防乙肝表面抗原血症有关。
